|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3B
|
|
pubmed:dateCreated |
2006-7-6
|
|
pubmed:abstractText |
No consensus exists regarding further therapy for the management of hormone-refractory prostate cancer. In this phase II study, the combination of Vinorelbine with 5-Fluorouracil and folinic acid (FLN regimen) was evaluated in patients with progressive or resistant disease after hormone therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
pubmed-author:AscioneGG,
pubmed-author:CuriglianoGG,
pubmed-author:DecobelliOO,
pubmed-author:GoldhirschAA,
pubmed-author:LocatelliMM,
pubmed-author:MateiVV,
pubmed-author:NolèFF,
pubmed-author:RoccaAA,
pubmed-author:SbanottoAA,
pubmed-author:ScardinoEE,
pubmed-author:VerriEE,
pubmed-author:VerweijFF,
pubmed-author:ZampinoM GMG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2375-80
|
|
pubmed:meshHeading |
pubmed-meshheading:16821619-Adenocarcinoma,
pubmed-meshheading:16821619-Aged,
pubmed-meshheading:16821619-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16821619-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16821619-Drug Administration Schedule,
pubmed-meshheading:16821619-Drug Resistance, Neoplasm,
pubmed-meshheading:16821619-Fluorouracil,
pubmed-meshheading:16821619-Humans,
pubmed-meshheading:16821619-Leucovorin,
pubmed-meshheading:16821619-Male,
pubmed-meshheading:16821619-Middle Aged,
pubmed-meshheading:16821619-Prostatic Neoplasms,
pubmed-meshheading:16821619-Vinblastine
|
|
pubmed:articleTitle |
Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
|
|
pubmed:affiliation |
Department of Medicine, European Institute of Oncology, 20141 Milan, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
